Watch these interviews on the iPad edition of this issue, conducted byOT reporter Sarah Maxwell
Preventing Hormone Receptor-Positive Breast Cancer-Latest from IBIS 1-3
Jack Cuzick, PhD, Director of the Wolfson Institute of Preventive Medicine and Head of the Centre for Cancer Prevention at Queen Mary University of London, discusses the most recent findings from the International Breast Cancer Intervention Studies: IBIS I and II studies, which used drugs targeting the estrogen receptor; and IBIS III, which compared use of an aromatase inhibitor, a bisphosphonate, and metformin for primary prevention.
New Strategies for Preventing ER-Negative Breast Cancer
Powel Brown MD, Chairman of the Department of Clinical Cancer Prevention at the University of Texas MD Anderson Cancer Center, discusses how estrogen receptor negative breast cancer might be prevented by strategies under investigation including HER2-targeting, vaccination, and treatment with metformin or retinoids.
Genetic Tests and Late Recurrence of Breast Cancer
Daniel F. Hayes, MD, Clinical Director of the Breast Oncology Program at the University of Michigan Cancer Center, notes that despite the proliferation of genetic tests for breast cancer recurrence risk, they cannot yet reliably be used to predict late recurrences.
Endocrine Therapy in Premenopausal Breast Cancer: Most Effective Not Always Best
Marco Colleoni, MD, of the European Institute of Oncology in Milan, said that for women with premenopausal breast cancer, the benefits of using the most effective adjuvant endocrine treatment need to be weighed against additional side effects. He discusses the criteria for individualizing optimal endocrine adjuvant treatments.
Deep Genomic Profiling for Breast Cancer
Fabrice Andre, MD, PhD, from Institut Gustave Roussy in France, noted that with actionable genomic alterations already being targeted by some existing approved drugs in patients with breast cancer, genomic analysis is being considered as a way to expand the range of individualized cancer drugs by revealing more pathways responsible for breast cancer response and outcome. He discusses how to bridge the gap between new genomic technologies and their application in the real world.
International Research and Consensus Needed to Interpret Breast Cancer Genomics Data
Peter Campbell MD, PhD, Head of Cancer Genetics and Genomics at the Sanger Institute in Cambridge and joint head of the Cancer Genome Project, said that understanding the emerging genomic landscape of breast cancer needs international research including large molecular screening projects. In the interview, he offers his insights into how breast cancer genomics can be applied in the clinic.
If you are not yet receiving our iPad issues, download the free Oncology Times app from the App Store today! Visithttp://bit.ly/OT-iPadApp, search in the App Store, or follow the link onhttp://oncology-times.com.